Cargando…
Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy
Approximately 30% patients with stage III colon cancer (CC) develop local recurrence and/or distant metastasis, even if postoperative adjuvant chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin (5-FU/LV) has been completed. In the present study, molecular analysis was performed to iden...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607086/ https://www.ncbi.nlm.nih.gov/pubmed/31423202 http://dx.doi.org/10.3892/ol.2019.10437 |
_version_ | 1783432024551325696 |
---|---|
author | Kumamoto, Kensuke Nakachi, Yutaka Mizuno, Yosuke Yokoyama, Masaru Ishibashi, Keiichiro Kosugi, Chihiro Koda, Keiji Kobayashi, Michiya Tanakaya, Kohji Matsunami, Toshio Eguchi, Hidetaka Okazaki, Yasushi Ishida, Hideyuki |
author_facet | Kumamoto, Kensuke Nakachi, Yutaka Mizuno, Yosuke Yokoyama, Masaru Ishibashi, Keiichiro Kosugi, Chihiro Koda, Keiji Kobayashi, Michiya Tanakaya, Kohji Matsunami, Toshio Eguchi, Hidetaka Okazaki, Yasushi Ishida, Hideyuki |
author_sort | Kumamoto, Kensuke |
collection | PubMed |
description | Approximately 30% patients with stage III colon cancer (CC) develop local recurrence and/or distant metastasis, even if postoperative adjuvant chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin (5-FU/LV) has been completed. In the present study, molecular analysis was performed to identify molecular markers of tumor recurrence in patients with stage III CC receiving oxaliplatin-based adjuvant chemotherapy. The FACOS study was conducted as a phase II study to evaluate the safety and efficacy of oxaliplatin-based treatment for stage III CC patients. Of the 132 CC patients enrolled in the present study, gene expression analysis using a microarray was conducted in 51 patients. Of these 51 patients, 6 developed recurrence within 5 years. The topmost 5% genes that showed differential expressions between cases that developed/did not develop recurrence were selected, and a set of predictive molecular markers for recurrence was identified. Of the 34,694 genes in the microarray, 1,734 genes were extracted as topmost 5% genes showing differential expressions between cases with and without recurrence. Among these, 10 genes, includingADH1A, ADH1C, CA12, CHP2, HMGCS2, SNAR-A1, TPI1, MS4A12, PLA2G10 and PTPRO, were identified as markers that could clearly divide patients with and without recurrence. Although several prediction models of tumor recurrence have been reported for CC, the set of 10 genes that the present study identified may be useful to predict the risk of recurrence in stage III CC patients receiving oxaliplatin-based adjuvant chemotherapy. Based on these results, high-risk patients with CC should be carefully observed to detect tumor recurrence during the follow-up period. |
format | Online Article Text |
id | pubmed-6607086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-66070862019-08-18 Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy Kumamoto, Kensuke Nakachi, Yutaka Mizuno, Yosuke Yokoyama, Masaru Ishibashi, Keiichiro Kosugi, Chihiro Koda, Keiji Kobayashi, Michiya Tanakaya, Kohji Matsunami, Toshio Eguchi, Hidetaka Okazaki, Yasushi Ishida, Hideyuki Oncol Lett Articles Approximately 30% patients with stage III colon cancer (CC) develop local recurrence and/or distant metastasis, even if postoperative adjuvant chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin (5-FU/LV) has been completed. In the present study, molecular analysis was performed to identify molecular markers of tumor recurrence in patients with stage III CC receiving oxaliplatin-based adjuvant chemotherapy. The FACOS study was conducted as a phase II study to evaluate the safety and efficacy of oxaliplatin-based treatment for stage III CC patients. Of the 132 CC patients enrolled in the present study, gene expression analysis using a microarray was conducted in 51 patients. Of these 51 patients, 6 developed recurrence within 5 years. The topmost 5% genes that showed differential expressions between cases that developed/did not develop recurrence were selected, and a set of predictive molecular markers for recurrence was identified. Of the 34,694 genes in the microarray, 1,734 genes were extracted as topmost 5% genes showing differential expressions between cases with and without recurrence. Among these, 10 genes, includingADH1A, ADH1C, CA12, CHP2, HMGCS2, SNAR-A1, TPI1, MS4A12, PLA2G10 and PTPRO, were identified as markers that could clearly divide patients with and without recurrence. Although several prediction models of tumor recurrence have been reported for CC, the set of 10 genes that the present study identified may be useful to predict the risk of recurrence in stage III CC patients receiving oxaliplatin-based adjuvant chemotherapy. Based on these results, high-risk patients with CC should be carefully observed to detect tumor recurrence during the follow-up period. D.A. Spandidos 2019-08 2019-06-05 /pmc/articles/PMC6607086/ /pubmed/31423202 http://dx.doi.org/10.3892/ol.2019.10437 Text en Copyright: © Kumamoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Kumamoto, Kensuke Nakachi, Yutaka Mizuno, Yosuke Yokoyama, Masaru Ishibashi, Keiichiro Kosugi, Chihiro Koda, Keiji Kobayashi, Michiya Tanakaya, Kohji Matsunami, Toshio Eguchi, Hidetaka Okazaki, Yasushi Ishida, Hideyuki Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy |
title | Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy |
title_full | Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy |
title_fullStr | Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy |
title_full_unstemmed | Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy |
title_short | Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy |
title_sort | expressions of 10 genes as candidate predictors of recurrence in stage iii colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607086/ https://www.ncbi.nlm.nih.gov/pubmed/31423202 http://dx.doi.org/10.3892/ol.2019.10437 |
work_keys_str_mv | AT kumamotokensuke expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT nakachiyutaka expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT mizunoyosuke expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT yokoyamamasaru expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT ishibashikeiichiro expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT kosugichihiro expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT kodakeiji expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT kobayashimichiya expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT tanakayakohji expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT matsunamitoshio expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT eguchihidetaka expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT okazakiyasushi expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy AT ishidahideyuki expressionsof10genesascandidatepredictorsofrecurrenceinstageiiicoloncancerpatientsreceivingadjuvantoxaliplatinbasedchemotherapy |